Table 3.
Clinical trials investigating bacterial consortia and probiotics
| Trial no. | Phase | Cancer type | Intervention | Sponsor/investigator |
|---|---|---|---|---|
| NCT03686202 | I | Solid tumors | MET-4 (defined bacterial consortia) + immune checkpoint inhibitors | University Health Network, Toronto |
| NCT03817125 | Ib | Melanoma | SER-401 (defined bacterial consortia) + immune checkpoint inhibitors | Parker Institute for Cancer Immunotherapy |
| NCT01895530 | – | Colorectal cancer | Supplement with probiotic Saccharomyces boulardii | Federal University of Minas Gerais |
| NCT03072641 | – | Colorectal cancer | Supplement with ProBion Clinica (Bifidobacterium lactis, Lactobacillus acidophilus, inulin) | Vastra Gotaland Region |
| NCT03782428 | – | Colorectal cancer | Probiotic with six viable micro-organisms of Lactobacillus spp. and Bifidobacterium spp. | National University of Malaysia |
| NCT03358511 | – | Breast cancer | Over-the-counter probiotic with 13 bacterial species | Mayo Clinic |